CN111650373A - 一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 - Google Patents
一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 Download PDFInfo
- Publication number
- CN111650373A CN111650373A CN202010665303.0A CN202010665303A CN111650373A CN 111650373 A CN111650373 A CN 111650373A CN 202010665303 A CN202010665303 A CN 202010665303A CN 111650373 A CN111650373 A CN 111650373A
- Authority
- CN
- China
- Prior art keywords
- artificial sequence
- cervical cancer
- ser
- gly
- prt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010008342 Cervix carcinoma Diseases 0.000 title claims abstract description 105
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title claims abstract description 105
- 201000010881 cervical cancer Diseases 0.000 title claims abstract description 105
- 239000003550 marker Substances 0.000 title claims abstract description 32
- 210000005259 peripheral blood Anatomy 0.000 title claims abstract description 15
- 239000011886 peripheral blood Substances 0.000 title claims abstract description 15
- 238000001514 detection method Methods 0.000 title abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 12
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 11
- 108091008874 T cell receptors Proteins 0.000 claims description 10
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 11
- 238000012165 high-throughput sequencing Methods 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract description 2
- 238000007405 data analysis Methods 0.000 abstract 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 58
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 27
- 206010028980 Neoplasm Diseases 0.000 description 23
- 230000003902 lesion Effects 0.000 description 13
- 108010026333 seryl-proline Proteins 0.000 description 11
- 108091008875 B cell receptors Proteins 0.000 description 9
- RFDHKPSHTXZKLL-IHRRRGAJSA-N Glu-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N RFDHKPSHTXZKLL-IHRRRGAJSA-N 0.000 description 9
- RCEHMXVEMNXRIW-IRIUXVKKSA-N Thr-Gln-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N)O RCEHMXVEMNXRIW-IRIUXVKKSA-N 0.000 description 9
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 6
- WAPFQMXRSDEGOE-IHRRRGAJSA-N Tyr-Glu-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O WAPFQMXRSDEGOE-IHRRRGAJSA-N 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 5
- QYXNFROWLZPWPC-FXQIFTODSA-N Asn-Glu-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QYXNFROWLZPWPC-FXQIFTODSA-N 0.000 description 5
- QOCFFCUFZGDHTP-NUMRIWBASA-N Asp-Thr-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOCFFCUFZGDHTP-NUMRIWBASA-N 0.000 description 5
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- NMKJPMCEKQHRPD-IRXDYDNUSA-N Tyr-Gly-Tyr Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NMKJPMCEKQHRPD-IRXDYDNUSA-N 0.000 description 4
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000002380 cytological effect Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 4
- 238000002559 palpation Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- VGPWRRFOPXVGOH-BYPYZUCNSA-N Ala-Gly-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)NCC(O)=O VGPWRRFOPXVGOH-BYPYZUCNSA-N 0.000 description 3
- BTKUIVBNGBFTTP-WHFBIAKZSA-N Ser-Ala-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)NCC(O)=O BTKUIVBNGBFTTP-WHFBIAKZSA-N 0.000 description 3
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 3
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 3
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 3
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 3
- 108010047495 alanylglycine Proteins 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 108010078144 glutaminyl-glycine Proteins 0.000 description 3
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 3
- 108010089804 glycyl-threonine Proteins 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000000439 tumor marker Substances 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- 238000011179 visual inspection Methods 0.000 description 3
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 2
- RTZCUEHYUQZIDE-WHFBIAKZSA-N Ala-Ser-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RTZCUEHYUQZIDE-WHFBIAKZSA-N 0.000 description 2
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 2
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 2
- HCZQKHSRYHCPSD-IUKAMOBKSA-N Asn-Thr-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HCZQKHSRYHCPSD-IUKAMOBKSA-N 0.000 description 2
- DRDSQGHKTLSNEA-GLLZPBPUSA-N Gln-Glu-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DRDSQGHKTLSNEA-GLLZPBPUSA-N 0.000 description 2
- ATRHMOJQJWPVBQ-DRZSPHRISA-N Glu-Ala-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ATRHMOJQJWPVBQ-DRZSPHRISA-N 0.000 description 2
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 2
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 description 2
- PDAWDNVHMUKWJR-ZETCQYMHSA-N Gly-Gly-His Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CNC=N1 PDAWDNVHMUKWJR-ZETCQYMHSA-N 0.000 description 2
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 2
- MKIAPEZXQDILRR-YUMQZZPRSA-N Gly-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN MKIAPEZXQDILRR-YUMQZZPRSA-N 0.000 description 2
- YDIDLLVFCYSXNY-RCOVLWMOSA-N Gly-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN YDIDLLVFCYSXNY-RCOVLWMOSA-N 0.000 description 2
- SBVMXEZQJVUARN-XPUUQOCRSA-N Gly-Val-Ser Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O SBVMXEZQJVUARN-XPUUQOCRSA-N 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- HDNOQCZWJGGHSS-VEVYYDQMSA-N Met-Asn-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O HDNOQCZWJGGHSS-VEVYYDQMSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 208000009608 Papillomavirus Infections Diseases 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- CMOIIANLNNYUTP-SRVKXCTJSA-N Pro-Gln-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O CMOIIANLNNYUTP-SRVKXCTJSA-N 0.000 description 2
- ULIWFCCJIOEHMU-BQBZGAKWSA-N Pro-Gly-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 ULIWFCCJIOEHMU-BQBZGAKWSA-N 0.000 description 2
- FYPGHGXAOZTOBO-IHRRRGAJSA-N Pro-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 FYPGHGXAOZTOBO-IHRRRGAJSA-N 0.000 description 2
- QUBVFEANYYWBTM-VEVYYDQMSA-N Pro-Thr-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O QUBVFEANYYWBTM-VEVYYDQMSA-N 0.000 description 2
- FZXSYIPVAFVYBH-KKUMJFAQSA-N Pro-Tyr-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O FZXSYIPVAFVYBH-KKUMJFAQSA-N 0.000 description 2
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 description 2
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 2
- FKYWFUYPVKLJLP-DCAQKATOSA-N Ser-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO FKYWFUYPVKLJLP-DCAQKATOSA-N 0.000 description 2
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 2
- XDARBNMYXKUFOJ-GSSVUCPTSA-N Thr-Asp-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDARBNMYXKUFOJ-GSSVUCPTSA-N 0.000 description 2
- XPNSAQMEAVSQRD-FBCQKBJTSA-N Thr-Gly-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)NCC(O)=O XPNSAQMEAVSQRD-FBCQKBJTSA-N 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 238000013473 artificial intelligence Methods 0.000 description 2
- 108010047857 aspartylglycine Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 108010006664 gamma-glutamyl-glycyl-glycine Proteins 0.000 description 2
- 108010087823 glycyltyrosine Proteins 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 108010009932 leucyl-alanyl-glycyl-valine Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- WXPZDDCNKXMOMC-AVGNSLFASA-N (2s)-1-[(2s)-2-[[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@H](C(O)=O)CCC1 WXPZDDCNKXMOMC-AVGNSLFASA-N 0.000 description 1
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 1
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 1
- WMYJZJRILUVVRG-WDSKDSINSA-N Ala-Gly-Gln Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O WMYJZJRILUVVRG-WDSKDSINSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- MDNAVFBZPROEHO-DCAQKATOSA-N Ala-Lys-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O MDNAVFBZPROEHO-DCAQKATOSA-N 0.000 description 1
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 1
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 1
- CQJHFKKGZXKZBC-BPNCWPANSA-N Ala-Pro-Tyr Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CQJHFKKGZXKZBC-BPNCWPANSA-N 0.000 description 1
- YYAVDNKUWLAFCV-ACZMJKKPSA-N Ala-Ser-Gln Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O YYAVDNKUWLAFCV-ACZMJKKPSA-N 0.000 description 1
- MSWSRLGNLKHDEI-ACZMJKKPSA-N Ala-Ser-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O MSWSRLGNLKHDEI-ACZMJKKPSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- OMCKWYSDUQBYCN-FXQIFTODSA-N Ala-Ser-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(O)=O OMCKWYSDUQBYCN-FXQIFTODSA-N 0.000 description 1
- UCDOXFBTMLKASE-HERUPUMHSA-N Ala-Ser-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N UCDOXFBTMLKASE-HERUPUMHSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- SAHQGRZIQVEJPF-JXUBOQSCSA-N Ala-Thr-Lys Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN SAHQGRZIQVEJPF-JXUBOQSCSA-N 0.000 description 1
- VHAQSYHSDKERBS-XPUUQOCRSA-N Ala-Val-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O VHAQSYHSDKERBS-XPUUQOCRSA-N 0.000 description 1
- MUXONAMCEUBVGA-DCAQKATOSA-N Arg-Arg-Gln Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(O)=O MUXONAMCEUBVGA-DCAQKATOSA-N 0.000 description 1
- BHSYMWWMVRPCPA-CYDGBPFRSA-N Arg-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N BHSYMWWMVRPCPA-CYDGBPFRSA-N 0.000 description 1
- RVDVDRUZWZIBJQ-CIUDSAMLSA-N Arg-Asn-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RVDVDRUZWZIBJQ-CIUDSAMLSA-N 0.000 description 1
- RFXXUWGNVRJTNQ-QXEWZRGKSA-N Arg-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)N RFXXUWGNVRJTNQ-QXEWZRGKSA-N 0.000 description 1
- UAOSDDXCTBIPCA-QXEWZRGKSA-N Arg-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UAOSDDXCTBIPCA-QXEWZRGKSA-N 0.000 description 1
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 description 1
- JEOCWTUOMKEEMF-RHYQMDGZSA-N Arg-Leu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JEOCWTUOMKEEMF-RHYQMDGZSA-N 0.000 description 1
- RIQBRKVTFBWEDY-RHYQMDGZSA-N Arg-Lys-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RIQBRKVTFBWEDY-RHYQMDGZSA-N 0.000 description 1
- UULLJGQFCDXVTQ-CYDGBPFRSA-N Arg-Pro-Ile Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UULLJGQFCDXVTQ-CYDGBPFRSA-N 0.000 description 1
- UZSQXCMNUPKLCC-FJXKBIBVSA-N Arg-Thr-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UZSQXCMNUPKLCC-FJXKBIBVSA-N 0.000 description 1
- VLIJAPRTSXSGFY-STQMWFEESA-N Arg-Tyr-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=C(O)C=C1 VLIJAPRTSXSGFY-STQMWFEESA-N 0.000 description 1
- IZSMEUDYADKZTJ-KJEVXHAQSA-N Arg-Tyr-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IZSMEUDYADKZTJ-KJEVXHAQSA-N 0.000 description 1
- LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
- QDXQWFBLUVTOFL-FXQIFTODSA-N Asn-Met-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(=O)N)N QDXQWFBLUVTOFL-FXQIFTODSA-N 0.000 description 1
- QXOPPIDJKPEKCW-GUBZILKMSA-N Asn-Pro-Arg Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O QXOPPIDJKPEKCW-GUBZILKMSA-N 0.000 description 1
- HPNDKUOLNRVRAY-BIIVOSGPSA-N Asn-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N)C(=O)O HPNDKUOLNRVRAY-BIIVOSGPSA-N 0.000 description 1
- HPASIOLTWSNMFB-OLHMAJIHSA-N Asn-Thr-Asp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O HPASIOLTWSNMFB-OLHMAJIHSA-N 0.000 description 1
- ZUFPUBYQYWCMDB-NUMRIWBASA-N Asn-Thr-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZUFPUBYQYWCMDB-NUMRIWBASA-N 0.000 description 1
- CBHVAFXKOYAHOY-NHCYSSNCSA-N Asn-Val-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O CBHVAFXKOYAHOY-NHCYSSNCSA-N 0.000 description 1
- BLQBMRNMBAYREH-UWJYBYFXSA-N Asp-Ala-Tyr Chemical compound N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O BLQBMRNMBAYREH-UWJYBYFXSA-N 0.000 description 1
- ILJQISGMGXRZQQ-IHRRRGAJSA-N Asp-Arg-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ILJQISGMGXRZQQ-IHRRRGAJSA-N 0.000 description 1
- NYQHSUGFEWDWPD-ACZMJKKPSA-N Asp-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N NYQHSUGFEWDWPD-ACZMJKKPSA-N 0.000 description 1
- HSWYMWGDMPLTTH-FXQIFTODSA-N Asp-Glu-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HSWYMWGDMPLTTH-FXQIFTODSA-N 0.000 description 1
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 1
- KOWYNSKRPUWSFG-IHPCNDPISA-N Asp-Phe-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)NC(=O)[C@H](CC(=O)O)N KOWYNSKRPUWSFG-IHPCNDPISA-N 0.000 description 1
- BWJZSLQJNBSUPM-FXQIFTODSA-N Asp-Pro-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(O)=O BWJZSLQJNBSUPM-FXQIFTODSA-N 0.000 description 1
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 1
- JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 1
- NUMFTVCBONFQIQ-DRZSPHRISA-N Gln-Ala-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NUMFTVCBONFQIQ-DRZSPHRISA-N 0.000 description 1
- ULXXDWZMMSQBDC-ACZMJKKPSA-N Gln-Asp-Asp Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N ULXXDWZMMSQBDC-ACZMJKKPSA-N 0.000 description 1
- IVCOYUURLWQDJQ-LPEHRKFASA-N Gln-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O IVCOYUURLWQDJQ-LPEHRKFASA-N 0.000 description 1
- ZQPOVSJFBBETHQ-CIUDSAMLSA-N Gln-Glu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZQPOVSJFBBETHQ-CIUDSAMLSA-N 0.000 description 1
- NSNUZSPSADIMJQ-WDSKDSINSA-N Gln-Gly-Asp Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O NSNUZSPSADIMJQ-WDSKDSINSA-N 0.000 description 1
- PIUPHASDUFSHTF-CIUDSAMLSA-N Gln-Pro-Asn Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)N)N)C(=O)N[C@@H](CC(=O)N)C(=O)O PIUPHASDUFSHTF-CIUDSAMLSA-N 0.000 description 1
- PBYFVIQRFLNQCO-GUBZILKMSA-N Gln-Pro-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O PBYFVIQRFLNQCO-GUBZILKMSA-N 0.000 description 1
- NPMFDZGLKBNFOO-SRVKXCTJSA-N Gln-Pro-His Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NPMFDZGLKBNFOO-SRVKXCTJSA-N 0.000 description 1
- KGNSGRRALVIRGR-QWRGUYRKSA-N Gln-Tyr Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KGNSGRRALVIRGR-QWRGUYRKSA-N 0.000 description 1
- WPJDPEOQUIXXOY-AVGNSLFASA-N Gln-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WPJDPEOQUIXXOY-AVGNSLFASA-N 0.000 description 1
- UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 1
- SBCYJMOOHUDWDA-NUMRIWBASA-N Glu-Asp-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SBCYJMOOHUDWDA-NUMRIWBASA-N 0.000 description 1
- XHUCVVHRLNPZSZ-CIUDSAMLSA-N Glu-Gln-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XHUCVVHRLNPZSZ-CIUDSAMLSA-N 0.000 description 1
- WLIPTFCZLHCNFD-LPEHRKFASA-N Glu-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N)C(=O)O WLIPTFCZLHCNFD-LPEHRKFASA-N 0.000 description 1
- OPAINBJQDQTGJY-JGVFFNPUSA-N Glu-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)O)N)C(=O)O OPAINBJQDQTGJY-JGVFFNPUSA-N 0.000 description 1
- ATVYZJGOZLVXDK-IUCAKERBSA-N Glu-Leu-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O ATVYZJGOZLVXDK-IUCAKERBSA-N 0.000 description 1
- WNRZUESNGGDCJX-JYJNAYRXSA-N Glu-Leu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WNRZUESNGGDCJX-JYJNAYRXSA-N 0.000 description 1
- UGSVSNXPJJDJKL-SDDRHHMPSA-N Glu-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)O)N UGSVSNXPJJDJKL-SDDRHHMPSA-N 0.000 description 1
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 1
- GMVCSRBOSIUTFC-FXQIFTODSA-N Glu-Ser-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMVCSRBOSIUTFC-FXQIFTODSA-N 0.000 description 1
- MWTGQXBHVRTCOR-GLLZPBPUSA-N Glu-Thr-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MWTGQXBHVRTCOR-GLLZPBPUSA-N 0.000 description 1
- GPSHCSTUYOQPAI-JHEQGTHGSA-N Glu-Thr-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O GPSHCSTUYOQPAI-JHEQGTHGSA-N 0.000 description 1
- PEKRLYMGPZFTCB-WNHJNPCNSA-N Glu-Trp-Asp-Arg Chemical compound N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O PEKRLYMGPZFTCB-WNHJNPCNSA-N 0.000 description 1
- BRFJMRSRMOMIMU-WHFBIAKZSA-N Gly-Ala-Asn Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O BRFJMRSRMOMIMU-WHFBIAKZSA-N 0.000 description 1
- RLFSBAPJTYKSLG-WHFBIAKZSA-N Gly-Ala-Asp Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O RLFSBAPJTYKSLG-WHFBIAKZSA-N 0.000 description 1
- UPOJUWHGMDJUQZ-IUCAKERBSA-N Gly-Arg-Arg Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UPOJUWHGMDJUQZ-IUCAKERBSA-N 0.000 description 1
- RQZGFWKQLPJOEQ-YUMQZZPRSA-N Gly-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN)CN=C(N)N RQZGFWKQLPJOEQ-YUMQZZPRSA-N 0.000 description 1
- GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 description 1
- XUORRGAFUQIMLC-STQMWFEESA-N Gly-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)O XUORRGAFUQIMLC-STQMWFEESA-N 0.000 description 1
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 1
- QGZSAHIZRQHCEQ-QWRGUYRKSA-N Gly-Asp-Tyr Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QGZSAHIZRQHCEQ-QWRGUYRKSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- NPSWCZIRBAYNSB-JHEQGTHGSA-N Gly-Gln-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NPSWCZIRBAYNSB-JHEQGTHGSA-N 0.000 description 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 1
- MBOAPAXLTUSMQI-JHEQGTHGSA-N Gly-Glu-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MBOAPAXLTUSMQI-JHEQGTHGSA-N 0.000 description 1
- UFPXDFOYHVEIPI-BYPYZUCNSA-N Gly-Gly-Asp Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O UFPXDFOYHVEIPI-BYPYZUCNSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- NTBOEZICHOSJEE-YUMQZZPRSA-N Gly-Lys-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O NTBOEZICHOSJEE-YUMQZZPRSA-N 0.000 description 1
- MTBIKIMYHUWBRX-QWRGUYRKSA-N Gly-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN MTBIKIMYHUWBRX-QWRGUYRKSA-N 0.000 description 1
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 1
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 1
- JNGHLWWFPGIJER-STQMWFEESA-N Gly-Pro-Tyr Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JNGHLWWFPGIJER-STQMWFEESA-N 0.000 description 1
- YOBGUCWZPXJHTN-BQBZGAKWSA-N Gly-Ser-Arg Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YOBGUCWZPXJHTN-BQBZGAKWSA-N 0.000 description 1
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 1
- JQFILXICXLDTRR-FBCQKBJTSA-N Gly-Thr-Gly Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)NCC(O)=O JQFILXICXLDTRR-FBCQKBJTSA-N 0.000 description 1
- UVTSZKIATYSKIR-RYUDHWBXSA-N Gly-Tyr-Glu Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O UVTSZKIATYSKIR-RYUDHWBXSA-N 0.000 description 1
- HQSKKSLNLSTONK-JTQLQIEISA-N Gly-Tyr-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 HQSKKSLNLSTONK-JTQLQIEISA-N 0.000 description 1
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 1
- NGRPGJGKJMUGDM-XVKPBYJWSA-N Gly-Val-Gln Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O NGRPGJGKJMUGDM-XVKPBYJWSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- PYNUBZSXKQKAHL-UWVGGRQHSA-N His-Gly-Arg Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O PYNUBZSXKQKAHL-UWVGGRQHSA-N 0.000 description 1
- VBOFRJNDIOPNDO-YUMQZZPRSA-N His-Gly-Asn Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N VBOFRJNDIOPNDO-YUMQZZPRSA-N 0.000 description 1
- JUIOPCXACJLRJK-AVGNSLFASA-N His-Lys-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N JUIOPCXACJLRJK-AVGNSLFASA-N 0.000 description 1
- 241000341655 Human papillomavirus type 16 Species 0.000 description 1
- DMHGKBGOUAJRHU-RVMXOQNASA-N Ile-Arg-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N DMHGKBGOUAJRHU-RVMXOQNASA-N 0.000 description 1
- DMHGKBGOUAJRHU-UHFFFAOYSA-N Ile-Arg-Pro Natural products CCC(C)C(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O DMHGKBGOUAJRHU-UHFFFAOYSA-N 0.000 description 1
- IDAHFEPYTJJZFD-PEFMBERDSA-N Ile-Asp-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N IDAHFEPYTJJZFD-PEFMBERDSA-N 0.000 description 1
- GYAFMRQGWHXMII-IUKAMOBKSA-N Ile-Asp-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N GYAFMRQGWHXMII-IUKAMOBKSA-N 0.000 description 1
- HTDRTKMNJRRYOJ-SIUGBPQLSA-N Ile-Gln-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HTDRTKMNJRRYOJ-SIUGBPQLSA-N 0.000 description 1
- FZWVCYCYWCLQDH-NHCYSSNCSA-N Ile-Leu-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)O)N FZWVCYCYWCLQDH-NHCYSSNCSA-N 0.000 description 1
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- KKXDHFKZWKLYGB-GUBZILKMSA-N Leu-Asn-Glu Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N KKXDHFKZWKLYGB-GUBZILKMSA-N 0.000 description 1
- FIJMQLGQLBLBOL-HJGDQZAQSA-N Leu-Asn-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FIJMQLGQLBLBOL-HJGDQZAQSA-N 0.000 description 1
- ILJREDZFPHTUIE-GUBZILKMSA-N Leu-Asp-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ILJREDZFPHTUIE-GUBZILKMSA-N 0.000 description 1
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 1
- OXRLYTYUXAQTHP-YUMQZZPRSA-N Leu-Gly-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(O)=O OXRLYTYUXAQTHP-YUMQZZPRSA-N 0.000 description 1
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 1
- DSFYPIUSAMSERP-IHRRRGAJSA-N Leu-Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DSFYPIUSAMSERP-IHRRRGAJSA-N 0.000 description 1
- OVZLLFONXILPDZ-VOAKCMCISA-N Leu-Lys-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OVZLLFONXILPDZ-VOAKCMCISA-N 0.000 description 1
- LZHJZLHSRGWBBE-IHRRRGAJSA-N Leu-Lys-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O LZHJZLHSRGWBBE-IHRRRGAJSA-N 0.000 description 1
- GCXGCIYIHXSKAY-ULQDDVLXSA-N Leu-Phe-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GCXGCIYIHXSKAY-ULQDDVLXSA-N 0.000 description 1
- BMVFXOQHDQZAQU-DCAQKATOSA-N Leu-Pro-Asp Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N BMVFXOQHDQZAQU-DCAQKATOSA-N 0.000 description 1
- JIHDFWWRYHSAQB-GUBZILKMSA-N Leu-Ser-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JIHDFWWRYHSAQB-GUBZILKMSA-N 0.000 description 1
- ISSAURVGLGAPDK-KKUMJFAQSA-N Leu-Tyr-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O ISSAURVGLGAPDK-KKUMJFAQSA-N 0.000 description 1
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 1
- XIZQPFCRXLUNMK-BZSNNMDCSA-N Lys-Leu-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCCCN)N XIZQPFCRXLUNMK-BZSNNMDCSA-N 0.000 description 1
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 1
- HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 1
- TVHCDSBMFQYPNA-RHYQMDGZSA-N Lys-Thr-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O TVHCDSBMFQYPNA-RHYQMDGZSA-N 0.000 description 1
- JHNOXVASMSXSNB-WEDXCCLWSA-N Lys-Thr-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JHNOXVASMSXSNB-WEDXCCLWSA-N 0.000 description 1
- UZWMJZSOXGOVIN-LURJTMIESA-N Met-Gly-Gly Chemical compound CSCC[C@H](N)C(=O)NCC(=O)NCC(O)=O UZWMJZSOXGOVIN-LURJTMIESA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- AYPMIIKUMNADSU-IHRRRGAJSA-N Phe-Arg-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O AYPMIIKUMNADSU-IHRRRGAJSA-N 0.000 description 1
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 1
- YYKZDTVQHTUKDW-RYUDHWBXSA-N Phe-Gly-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N YYKZDTVQHTUKDW-RYUDHWBXSA-N 0.000 description 1
- AAERWTUHZKLDLC-IHRRRGAJSA-N Phe-Pro-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O AAERWTUHZKLDLC-IHRRRGAJSA-N 0.000 description 1
- ZJPGOXWRFNKIQL-JYJNAYRXSA-N Phe-Pro-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 ZJPGOXWRFNKIQL-JYJNAYRXSA-N 0.000 description 1
- XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 1
- LNLNHXIQPGKRJQ-SRVKXCTJSA-N Pro-Arg-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1 LNLNHXIQPGKRJQ-SRVKXCTJSA-N 0.000 description 1
- WWAQEUOYCYMGHB-FXQIFTODSA-N Pro-Asn-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1 WWAQEUOYCYMGHB-FXQIFTODSA-N 0.000 description 1
- ZPPVJIJMIKTERM-YUMQZZPRSA-N Pro-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ZPPVJIJMIKTERM-YUMQZZPRSA-N 0.000 description 1
- LHALYDBUDCWMDY-CIUDSAMLSA-N Pro-Glu-Ala Chemical compound C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1)C(O)=O LHALYDBUDCWMDY-CIUDSAMLSA-N 0.000 description 1
- FRKBNXCFJBPJOL-GUBZILKMSA-N Pro-Glu-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O FRKBNXCFJBPJOL-GUBZILKMSA-N 0.000 description 1
- DMKWYMWNEKIPFC-IUCAKERBSA-N Pro-Gly-Arg Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O DMKWYMWNEKIPFC-IUCAKERBSA-N 0.000 description 1
- UUHXBJHVTVGSKM-BQBZGAKWSA-N Pro-Gly-Asn Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UUHXBJHVTVGSKM-BQBZGAKWSA-N 0.000 description 1
- CLJLVCYFABNTHP-DCAQKATOSA-N Pro-Leu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O CLJLVCYFABNTHP-DCAQKATOSA-N 0.000 description 1
- ZUZINZIJHJFJRN-UBHSHLNASA-N Pro-Phe-Ala Chemical compound C([C@@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 ZUZINZIJHJFJRN-UBHSHLNASA-N 0.000 description 1
- RTQKBZIRDWZLDF-BZSNNMDCSA-N Pro-Pro-Trp Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)O)CCN1C(=O)[C@@H]1CCCN1 RTQKBZIRDWZLDF-BZSNNMDCSA-N 0.000 description 1
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 1
- SEZGGSHLMROBFX-CIUDSAMLSA-N Pro-Ser-Gln Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O SEZGGSHLMROBFX-CIUDSAMLSA-N 0.000 description 1
- VEUACYMXJKXALX-IHRRRGAJSA-N Pro-Tyr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VEUACYMXJKXALX-IHRRRGAJSA-N 0.000 description 1
- MTMJNKFZDQEVSY-BZSNNMDCSA-N Pro-Val-Trp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O MTMJNKFZDQEVSY-BZSNNMDCSA-N 0.000 description 1
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
- QGMLKFGTGXWAHF-IHRRRGAJSA-N Ser-Arg-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QGMLKFGTGXWAHF-IHRRRGAJSA-N 0.000 description 1
- NRCJWSGXMAPYQX-LPEHRKFASA-N Ser-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N)C(=O)O NRCJWSGXMAPYQX-LPEHRKFASA-N 0.000 description 1
- FIDMVVBUOCMMJG-CIUDSAMLSA-N Ser-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO FIDMVVBUOCMMJG-CIUDSAMLSA-N 0.000 description 1
- BNFVPSRLHHPQKS-WHFBIAKZSA-N Ser-Asp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O BNFVPSRLHHPQKS-WHFBIAKZSA-N 0.000 description 1
- ZOHGLPQGEHSLPD-FXQIFTODSA-N Ser-Gln-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZOHGLPQGEHSLPD-FXQIFTODSA-N 0.000 description 1
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- OQPNSDWGAMFJNU-QWRGUYRKSA-N Ser-Gly-Tyr Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 OQPNSDWGAMFJNU-QWRGUYRKSA-N 0.000 description 1
- JLKWJWPDXPKKHI-FXQIFTODSA-N Ser-Pro-Asn Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CC(=O)N)C(=O)O JLKWJWPDXPKKHI-FXQIFTODSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 1
- VLMIUSLQONKLDV-HEIBUPTGSA-N Ser-Thr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VLMIUSLQONKLDV-HEIBUPTGSA-N 0.000 description 1
- PQEQXWRVHQAAKS-SRVKXCTJSA-N Ser-Tyr-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)N)CC1=CC=C(O)C=C1 PQEQXWRVHQAAKS-SRVKXCTJSA-N 0.000 description 1
- QYBRQMLZDDJBSW-AVGNSLFASA-N Ser-Tyr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O QYBRQMLZDDJBSW-AVGNSLFASA-N 0.000 description 1
- JZRYFUGREMECBH-XPUUQOCRSA-N Ser-Val-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O JZRYFUGREMECBH-XPUUQOCRSA-N 0.000 description 1
- HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 1
- ODRUTDLAONAVDV-IHRRRGAJSA-N Ser-Val-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ODRUTDLAONAVDV-IHRRRGAJSA-N 0.000 description 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 description 1
- GLQFKOVWXPPFTP-VEVYYDQMSA-N Thr-Arg-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O GLQFKOVWXPPFTP-VEVYYDQMSA-N 0.000 description 1
- VFEHSAJCWWHDBH-RHYQMDGZSA-N Thr-Arg-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O VFEHSAJCWWHDBH-RHYQMDGZSA-N 0.000 description 1
- JEDIEMIJYSRUBB-FOHZUACHSA-N Thr-Asp-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O JEDIEMIJYSRUBB-FOHZUACHSA-N 0.000 description 1
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 1
- GKWNLDNXMMLRMC-GLLZPBPUSA-N Thr-Glu-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O GKWNLDNXMMLRMC-GLLZPBPUSA-N 0.000 description 1
- LHEZGZQRLDBSRR-WDCWCFNPSA-N Thr-Glu-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LHEZGZQRLDBSRR-WDCWCFNPSA-N 0.000 description 1
- KCRQEJSKXAIULJ-FJXKBIBVSA-N Thr-Gly-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O KCRQEJSKXAIULJ-FJXKBIBVSA-N 0.000 description 1
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 1
- CYVQBKQYQGEELV-NKIYYHGXSA-N Thr-His-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O CYVQBKQYQGEELV-NKIYYHGXSA-N 0.000 description 1
- IHAPJUHCZXBPHR-WZLNRYEVSA-N Thr-Ile-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N IHAPJUHCZXBPHR-WZLNRYEVSA-N 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- STUAPCLEDMKXKL-LKXGYXEUSA-N Thr-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O STUAPCLEDMKXKL-LKXGYXEUSA-N 0.000 description 1
- RVMNUBQWPVOUKH-HEIBUPTGSA-N Thr-Ser-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RVMNUBQWPVOUKH-HEIBUPTGSA-N 0.000 description 1
- GQPQJNMVELPZNQ-GBALPHGKSA-N Thr-Ser-Trp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N)O GQPQJNMVELPZNQ-GBALPHGKSA-N 0.000 description 1
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 1
- IQGJAHMZWBTRIF-UBHSHLNASA-N Trp-Asp-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N IQGJAHMZWBTRIF-UBHSHLNASA-N 0.000 description 1
- OFTGYORHQMSPAI-PJODQICGSA-N Trp-Met-Ala Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O OFTGYORHQMSPAI-PJODQICGSA-N 0.000 description 1
- PEVVXUGSAKEPEN-AVGNSLFASA-N Tyr-Asn-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PEVVXUGSAKEPEN-AVGNSLFASA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- BARBHMSSVWPKPZ-IHRRRGAJSA-N Tyr-Asp-Arg Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BARBHMSSVWPKPZ-IHRRRGAJSA-N 0.000 description 1
- HVHJYXDXRIWELT-RYUDHWBXSA-N Tyr-Glu-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O HVHJYXDXRIWELT-RYUDHWBXSA-N 0.000 description 1
- ZRPLVTZTKPPSBT-AVGNSLFASA-N Tyr-Glu-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZRPLVTZTKPPSBT-AVGNSLFASA-N 0.000 description 1
- NOOMDULIORCDNF-IRXDYDNUSA-N Tyr-Gly-Phe Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NOOMDULIORCDNF-IRXDYDNUSA-N 0.000 description 1
- HSBZWINKRYZCSQ-KKUMJFAQSA-N Tyr-Lys-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O HSBZWINKRYZCSQ-KKUMJFAQSA-N 0.000 description 1
- QKXAEWMHAAVVGS-KKUMJFAQSA-N Tyr-Pro-Glu Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O QKXAEWMHAAVVGS-KKUMJFAQSA-N 0.000 description 1
- QFXVAFIHVWXXBJ-AVGNSLFASA-N Tyr-Ser-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O QFXVAFIHVWXXBJ-AVGNSLFASA-N 0.000 description 1
- ZPFLBLFITJCBTP-QWRGUYRKSA-N Tyr-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O ZPFLBLFITJCBTP-QWRGUYRKSA-N 0.000 description 1
- QPOUERMDWKKZEG-HJPIBITLSA-N Tyr-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 QPOUERMDWKKZEG-HJPIBITLSA-N 0.000 description 1
- GZWPQZDVTBZVEP-BZSNNMDCSA-N Tyr-Tyr-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O GZWPQZDVTBZVEP-BZSNNMDCSA-N 0.000 description 1
- WYOBRXPIZVKNMF-IRXDYDNUSA-N Tyr-Tyr-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 WYOBRXPIZVKNMF-IRXDYDNUSA-N 0.000 description 1
- ASQFIHTXXMFENG-XPUUQOCRSA-N Val-Ala-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O ASQFIHTXXMFENG-XPUUQOCRSA-N 0.000 description 1
- JLFKWDAZBRYCGX-ZKWXMUAHSA-N Val-Asn-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N JLFKWDAZBRYCGX-ZKWXMUAHSA-N 0.000 description 1
- VLOYGOZDPGYWFO-LAEOZQHASA-N Val-Asp-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VLOYGOZDPGYWFO-LAEOZQHASA-N 0.000 description 1
- BVWPHWLFGRCECJ-JSGCOSHPSA-N Val-Gly-Tyr Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N BVWPHWLFGRCECJ-JSGCOSHPSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 108010045023 alanyl-prolyl-tyrosine Proteins 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 1
- 108010068380 arginylarginine Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010068265 aspartyltyrosine Proteins 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 1
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 1
- 108010048994 glycyl-tyrosyl-alanine Proteins 0.000 description 1
- 108010045126 glycyl-tyrosyl-glycine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108010051242 phenylalanylserine Proteins 0.000 description 1
- 108010025488 pinealon Proteins 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 108010007375 seryl-seryl-seryl-arginine Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 108010038745 tryptophylglycine Proteins 0.000 description 1
- 108010044292 tryptophyltyrosine Proteins 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57411—Specifically defined cancers of cervix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种宫颈癌的外周血TCR标志物及其检测试剂盒和应用。该标志物包括序列为SEQ ID NO.1~100所示的蛋白中的至少一种。本发明基于高通量测序方法,只需要采取少量外周血,提取RNA,通过对样本的处理建立免疫图谱文库,再经过高通量测序和TCR数据分析,首先确定宫颈癌外周血中特征性TCR序列,然后将待测样本测试结果与该特征性TCR序列比对,从而确定是否患有宫颈癌。本发明能够同时比较巨大数量的宫颈癌特异性TCR序列,相比单独检测一种或几种标记物,具有更高的特异性和准确性,提高了诊断效率。
Description
技术领域
本发明属于基因工程技术领域,具体涉及一种宫颈癌的外周血TCR标志物及其检测试剂盒和应用。
背景技术
根据CGCS第26届中国肿瘤防治协会报告,每年新发宫颈癌病例在50万左右(世界范围),80%以上的病例发生在发展中国家。我国每年新发病例约13万,占全世界新发病例总数的28%。2018年发布的ICO中国HPV和相关疾病报告显示,在中国15-44岁女性中,子宫颈癌的发病率高居恶性肿瘤第三位,以成为女性癌症死亡的第二大原因。中国2018年约有47739名女性因子宫颈癌死亡。且子宫颈癌死亡率呈上升趋势,威胁中国女性生命安全。高危型别HPV持续感染是子宫颈癌的主要致病“元凶”.HPV感染率很高,一项基于美国人群的研究显示,有性行为的男性和女性一生中感染HPV的几率高达85%-90%。大多数感染可以依靠自身的免疫力清除。小部分患者高危型别HPV持续感染,经数十年时间可导致病变并最终进展为子宫颈癌。
中国女性约98%的子宫颈癌由高危型HPV导致,其中69%子宫颈癌有高危型别HPV16/18感染,23%子宫颈癌有高危型别HPV31/33/45/52/58感染,其他高危型别HPV感染致癌率达6%。目前,子宫颈癌的综合防控主要分为三级。以减少HPV感染为一级预防:1.健康教育;2、接种HPV疫苗。对癌前病变进行筛查、诊断和治疗为二级预防(最有效可控的预防阶段),现有的主要筛查方法主要有:宫颈细胞学涂片、HPV检测、阴道镜检查后的随访管理。三级预防也是最无奈的方式,对子宫颈癌进行治疗。
目前针对卵巢癌的诊断手段主要分为视诊、触诊、细胞学涂片检查、组织学检查、腔镜检查、影像学检查、肿瘤标志物检查。
1、视诊:在充足照明条件下,直接观察外阴和通过阴道窥器观察阴道及宫颈。可直接观察癌浸范围,肿瘤位置、范围、形态、体积及与周围组织的关系,但收视线范围及肿瘤大小影响,有局限性且无法定性。
2、触诊:肿瘤的质地、浸润范围及其与周围的关系等必须通过触诊确定。有些黏膜下及颈管内浸润,触诊比视诊更准确。但依旧受接触面积等人为因素影响,且对肿瘤无法定性。
3、细胞学涂片检查及组织学检查:细胞学涂片检查目前为发现宫颈癌前病变和早期宫颈癌的主要手段,特别是对临床体征不明显的早期病变的诊断。宫颈癌前病变和早期宫颈癌的诊断均应有活体组织学检查证实。大多采用液基细胞学检查法(TCT),很少给患者带来痛苦,是目前比较有效的防癌方法。由于我国病理医生的缺乏,涂片的阅读准确性很难达到100%。目前也没有数据证实,现有的检查手段能明显降低人群总体上因宫颈癌病死的人数。关键的还是合理的筛查时间间隔且适龄女性一定要记得复查。
4、腔镜检查:对发现宫颈癌前病变、早期宫颈癌、确定病变部位有重要作用,可提高活检的阳性率。接受阴道镜活检均要做颈管刮术。在强光源照射下通过阴道镜直接观察阴道,放大6-20倍,借以观察肉眼看不到的阴道和宫颈的较微小病变。在可疑部分行定位活检,可提高确诊率。由于临近膀胱组织,活检取样是有比较大的难度,因此对临床医生的要求较高,需要临床医生有比较全面的妇产科手术经验。整个检查过程由于属于侵入性检测,患者需要忍受不适而且活检后普遍需要10-14天的时间恢复。此操作对医院的诊疗条件有一定要求,不具备相应条件的需要转诊上级医院。
5、影像学检查
由于解剖部位表浅,绝大多数宫颈癌经妇科检查及细胞病理学检查即可被确诊。在宫颈癌诊断中影像学检查的价值主要是对肿瘤转移、侵犯范围和程度的了解,以指导临床决策并用于疗效评价。
(1)腹盆腔超声:主要用于宫颈局部病变的观察,同时可以观察盆腔及腹膜后区淋巴结转移情况,以及腹盆腔其它脏器的转移情况。但设备的优劣及操作者经验影响诊断的正确率。
(2)盆腔MRI:依照MRI表现提高术前分期的准确率。同时也可观察双侧腹股沟、盆腔及腹膜后区淋巴结转移的情况。
(3)腹盆腔CT:平扫CT观察宫颈局部病变效果不好,尤其是分期较早的病变;增强CT扫描利于宫颈局部病变的显示,但仍有近50%的病变呈等密度,不能清晰显示。
3、血肿瘤标志物检查方法
肿瘤标志物异常升高可以协助诊断、疗效评价、病情监测和治疗后的随访监测,SCC作为宫颈鳞状细胞癌的重要逼走植物,血清SCC水平超过1.5ng/ml被视为异常。但肿瘤标志物只能起到协助诊断的功能,不能作为宫颈癌确诊的依据。
发明内容
针对现有技术中的上述不足,本发明提供一种宫颈癌的外周血TCR标志物及其检测试剂盒和应用,能准确快速的判断待测样本中是否有较高宫颈癌风险患者。
为实现上述目的,本发明解决其技术问题所采用的技术方案是:
一种宫颈癌的外周血TCR标志物,该标志物包括序列为SEQ ID NO.1~100所示的蛋白中的至少一种,具体序列见表1。
表1标志物序列
进一步地,标志物的蛋白序列为SEQ ID NO.1~100所示的序列经取代、缺失和/或替换一个或多个碱基后,能表达相同功能的蛋白。
进一步地,标志物为外周血TCR标志物CDR3序列。
上述标志物在制备治疗宫颈癌的制剂中的应用。
进一步地,制剂中包括含有该标志物的T细胞受体,或能表达产生该标志物的T细胞受体的质粒、病毒载体或核酸片段。
一种用于宫颈癌检测的试剂盒,包括能与上述标志物发生特异性结合的抗体。
一种制剂,包括能与上述标志物发生特异性结合的抗体;所述制剂可用于对宫颈癌进行诊断、预测、检测或筛查。
一种检测宫颈癌的蛋白质芯片,该蛋白质芯片包括基片和点样在基片上特异性抗体,该特异性抗体为能与上述标志物发生特异性结合的抗体。
本发明的原理为:人体内的B淋巴细胞和T淋巴细胞是获得性免疫系统中重要的两类细胞。B细胞通过细胞表面的B细胞受体(BCR)识别抗原,后期BCR在B细胞分化成浆细胞时,表达成抗体,分泌到细胞外。T细胞通过细胞表面的T细胞受体(TCR)识别抗原。BCR和TCR的多样性是建立获得性免疫系统的基础。BCR多样性的理论值是1018,TCR多样性的理论值是1014。BCR与TCR序列中,抗原决定簇3(CDR3)是决定其抗原特异性最重要的部分,因此CDR3的序列被认为可以代表BCR、TCR序列的特性。
在各种疾病中,随着不同的抗原刺激,BCR和TCR的多样性或者表达水平都会发生改变。因此,利用BCR或者TCR高通量测序结果可以追踪疾病的发生、发展。人体内细胞中,衰老蛋白质降解后,其片段会被运输到细胞表面,通过组织相容性抗原II(MCHII)呈递给免疫系统中的T细胞。正常细胞呈递的抗原片段,由于免疫耐受的关系,不会引起免疫反应。一旦当正常细胞出现癌变后,突变的基因表达的异常蛋白,其片段被呈递到细胞表面后,就会引起人体免疫系统产生针对性的免疫反应。因此,分析BCR或TCR的变化,能够检测出肿瘤的发生和发展。
本发明的有益效果为:
1、本发明中,首先利用1300个非宫颈癌的对照组样本、和100个宫颈癌病人的TCR高通量测序数据建立了人工智能分析模型,通过和这些宫颈癌特异性TCR序列对比,可以清楚的判断待测样本中是否有较高宫颈癌风险者。
2、通过高通量测序分析TCR变化可以发现很早期的宫颈癌,利用宫颈癌特有的TCRCDR3序列分析人的免疫系统中的T细胞对宫颈癌的反应,是一种新型的检测方法。
3、本发明通过采用高通量测序技术同时比较数量巨大的特异性TCR序列,比起单独检测一种或几种标记物,具有更高的特异性和准确性。
4、本发明中使用的高通量测序仪器成本低于大型影像学设备,且可向第三方外包,此外,采样、处理的人力成本低于同时检测多种标记物,也低于大量细胞学检测,因此,本发明大大降低了检测成本。
5、本发明只需要采取少量外周血,采样简便、安全。
6、本发明中所述TCR CDR3序列,可用于宫颈癌的免疫治疗。
附图说明
图1为本发明中,对照组CDR3序列及宫颈癌特征序列。横坐标代表某一特定氨基酸组合的CDR3序列被加入对照序列集合或宫颈癌特征序列集合的先后顺序,纵坐标代表该序列在某一样本中重复出现次数CX的对数值;宫颈癌患者的免疫图谱具有多个种类且重复次数较高的宫颈癌特征序列,健康人极少宫颈癌特征序列,而未知受试者的宫颈癌特征比较明显,说明罹患宫颈癌风险较高。
图2为本发明中,针对宫颈癌特征序列集,计算健康人、非肿瘤病人、非宫颈癌肿瘤患者和宫颈癌患者的宫颈癌特征性指数,健康人、非肿瘤病人、非宫颈癌肿瘤患者的宫颈癌特征性指数均与宫颈癌患者具有显著差异,证明了宫颈癌特征序列集的特异性。据此可以判断未知受试者是否罹患宫颈癌。
具体实施方式
下面对本发明的具体实施方式进行描述,以便于本技术领域的技术人员理解本发明,但应该清楚,本发明不限于具体实施方式的范围,对本技术领域的普通技术人员来讲,只要各种变化在所附的权利要求限定和确定的本发明的精神和范围内,这些变化是显而易见的,一切利用本发明构思的发明创造均在保护之列。
实施例1通过免疫图谱分析,获得宫颈癌TCR标志物CDR3序列集
1、采样及免疫图谱分析(方法参考专利ZL201910300069.9)
采集1301名对照组(包括健康人和非肿瘤疾病病人,1300人用于建立模型,1个健康人用于验证)、101名宫颈癌患者(100人用于建立模型,1人用于验证)及1名未知健康状况受试者的外周血(每人10mL),通过高通量测序得到受试者和对照组的TCR的抗原决定簇3(CDR3)氨基酸序列,保证每个样本的功能性TCR的CDR3序列总数综合不低于30000;
2、对每个样本的TCR的CDR3序列进行随机不放回抽样,使每个样本的CDR3序列数量总和均为30000。对任一特定CDR3序列X,在单样本测序结果中重复出现次数计为CX;
3、通过分析TCR CDR3数据,确定宫颈癌TCR标志物CDR3序列:
a)将1300名用于建立模型的对照组样本的所有CDR3序列归总去重,设为对照序列集;
b)将100名用于建立模型的宫颈癌样本的所有CDR3序列归总去重,再去除所有与对照序列集中包含序列重复的序列,设为宫颈癌特征序列集。作图如附图1A所示,其中横坐标代表某一特定氨基酸组合的CDR3序列被加入对照序列集合或宫颈癌特征序列集合的先后顺序,纵坐标代表该序列在某一样本中重复出现次数CX的对数值。
c)按照同样作图方法,将1名健康人、1名宫颈癌患者和1名健康状况未知受试者的免疫图谱,参照对照序列集合和宫颈癌特征序列集合进行作图,见附图1B-D。从图中可见,宫颈癌患者的免疫图谱中,含有较多种类且较高重复出现次数的宫颈癌特征序列;健康人的免疫图谱中,只有极少量宫颈癌特征序列;而未知健康状况受试者,有高于健康人的宫颈癌特征序列,说明此人有较高风险罹患宫颈癌。
d)将宫颈癌特征序列集中,将所有出现在两个及以上参与建模宫颈癌样本里的CDR3序列,按“所有参与建模宫颈癌样本里该序列单样本中重复出现次数CX的总和×包含该序列的参与建模宫颈癌样本数”从高到低排序,排名前100者即为宫颈癌TCR标志物CDR3序列,具体序列如SEQ ID NO.1~100所示。
实施例2验证宫颈癌TCR标志物CDR3序列集的特异性
1、采样及免疫图谱分析(方法参考专利ZL201910300069.9)
采集250名非宫颈癌的肿瘤患者、30名未知健康状况受试者的外周血(每人10mL),通过高通量测序得到受试者和对照组的TCR的抗原决定簇3(CDR3)氨基酸序列,保证每个样本的功能性TCR的CDR3序列总数综合不低于30000;对每个样本的TCR的CDR3序列进行随机不放回抽样,使每个样本的CDR3序列数量总和均为30000。
2、从实施例1的对照组中随机挑选100名健康人及45名非肿瘤疾病病人。
3、根据来自实施例1的100名健康人、45名非肿瘤疾病病人、100名宫颈癌患者,以及实施例2新获取的250名非宫颈癌肿瘤患者、30名未知健康状况受试者的免疫图谱,分析其宫颈癌特征性指数。
其中宫颈癌特征性指数定义为:某个样本中,属于宫颈癌特征序列集的所有CDR3序列在该样本内重复出现次数CX的总和。分析结果见下表2及附图2。宫颈癌组与健康人(p=1.1E-121)、非肿瘤疾病(p=1.7E-73)、其它肿瘤(p=7.4E-220)都有显著差异,这证明了宫颈癌特征序列集的特异性。
表2不同样本组的宫颈癌特征性指数
4、分析各组的宫颈癌特征指数(表3),未知健康状况受试者(检测样本)中,前17人的宫颈癌特征指数高于“其它肿瘤”组的平均值+2×SD(362+2×719=1800),此4人具有较高风险罹患宫颈癌;后13人宫颈癌特征指数接近健康人或非肿瘤疾病组平均值,罹患宫颈癌风险低。与临床体检结果对照后,前17人确为宫颈癌患者,而后13人为健康人。此实施例证明了利用宫颈癌特征序列集及宫颈癌特征性指数,预测受试者罹患宫颈癌风险的可行性。
表3宫颈癌特征性指数分析
健康人 | 非肿瘤疾病 | 其他肿瘤 | 宫颈癌 | 检测样本 | |
Mean | 110.08 | 206.36 | 362.37 | 12914.91 | 3243.30 |
SD | 37.22 | 592.90 | 718.92 | 2334.05 | 3572.74 |
mean+2SD | 184.52 | 1392.15 | 1800.21 |
综上所述,本发明所述宫颈癌TCR标志物CDR3序列,确实具有显著的宫颈癌特异性,不仅可以用于宫颈癌预测受试者罹患宫颈癌风险,未来还可用于宫颈癌的生物免疫治疗。
序列表
<110> 成都益安博生物技术有限公司
<120> 一种宫颈癌的外周血TCR标志物及其检测试剂盒和应用
<160> 100
<170> SIPOSequenceListing 1.0
<210> 1
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Ala Ser Thr Tyr Pro Glu Gly Gly Glu Lys Leu Phe
1 5 10
<210> 2
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Ala Ser Ser Glu Lys Thr Tyr Ser Gly Asn Thr Ile Tyr
1 5 10
<210> 3
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Ala Ser Gly Arg Ala Leu Gly Leu Pro Asp Arg Lys Thr Gln Tyr
1 5 10 15
<210> 4
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Ser Val Glu Arg Ile Gly Ile Thr Thr Gly Glu Leu Phe
1 5 10
<210> 5
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Ala Ser Ser Gly Pro Thr Ser Gly Glu Gly Val Asn Glu Gln Phe
1 5 10 15
<210> 6
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Ala Ser Ser Tyr Lys Asp Pro Asn Asn Tyr Gly Tyr Thr
1 5 10
<210> 7
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Ala Ser Ser Lys Leu Ser Gly Tyr Gly Tyr Thr
1 5 10
<210> 8
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Ala Ser Ser Asn Met Ala Gly Glu Thr Gln Tyr
1 5 10
<210> 9
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 9
Ala Ser Ser Pro Glu Glu Ala Pro Tyr Asn Ser Pro Leu His
1 5 10
<210> 10
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 10
Ala Ser Ser Phe Pro Asp Arg Tyr Gly Glu Gln Phe
1 5 10
<210> 11
<211> 18
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Ala Ser Ser Tyr Glu Gly Gly Gln Gly Leu Lys Thr Pro Thr Asp Thr
1 5 10 15
Gln Tyr
<210> 12
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Ala Ser Ser Ala Ser Trp Gly Tyr Glu Gln Tyr
1 5 10
<210> 13
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 13
Ala Ser Arg Pro Gly Arg Glu Gln Pro Gln His
1 5 10
<210> 14
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 14
Ala Ser Ser Leu Thr Ser Gly Arg Tyr Gly Thr Asp Thr Gln Tyr
1 5 10 15
<210> 15
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 15
Ser Glu Leu His Gly Arg Asn Thr Glu Ala Phe
1 5 10
<210> 16
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 16
Ala Ser Ser Tyr Asp Arg Gly Lys Ser His Gly Asn Thr Ile Tyr
1 5 10 15
<210> 17
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 17
Ser Val Glu Asp Pro Asn Gly Leu Gly Arg Tyr Thr
1 5 10
<210> 18
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 18
Ala Thr Ser Asn Pro Arg Gly Glu Glu Thr Gln Tyr
1 5 10
<210> 19
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 19
Ala Ser Ser Pro Pro Trp Glu Asp Thr Asp Thr Gln Tyr
1 5 10
<210> 20
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 20
Ala Ser Ser Glu Leu Gly Lys Ser Ala Gly Ala Asn Val Leu Thr
1 5 10 15
<210> 21
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 21
Ala Ser Ser Ser Ala Gly Thr Ser Trp Phe
1 5 10
<210> 22
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 22
Ser Val Phe Ser Gly Gly Gly Gly Asp Thr Glu Ala Phe
1 5 10
<210> 23
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 23
Ala Thr Ser Asp Phe Trp Thr Ser Gly Asn Thr Asp Thr Gln Tyr
1 5 10 15
<210> 24
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 24
Ala Ser Ser Asp Thr Gly Thr Gly Gly Tyr Tyr Gly Tyr Thr
1 5 10
<210> 25
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 25
Ala Ser Ser Pro Thr Asp Gly Val Ser Gln Pro Gln His
1 5 10
<210> 26
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 26
Ser Ala Arg Asp Val Asp Leu Gln Asn Ser Pro Leu His
1 5 10
<210> 27
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 27
Ala Ser Arg Arg Pro Ile Asn Glu Gln Phe
1 5 10
<210> 28
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 28
Ala Ser Gln Gly Phe Thr Ser Gly Gly Asn Asn Glu Gln Phe
1 5 10
<210> 29
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 29
Ala Ser Ser Gln Ala Phe Gly Ala Asp Tyr Tyr Asn Glu Gln Phe
1 5 10 15
<210> 30
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 30
Ala Ser Gly Leu Gly Thr Thr His Gln Pro Gln His
1 5 10
<210> 31
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 31
Ala Thr Gly Leu Ala Gly Gln Tyr Asn Glu Gln Phe
1 5 10
<210> 32
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 32
Ala Ser Arg Ser Gly Glu Gly Phe Asn Glu Gln Phe
1 5 10
<210> 33
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 33
Ala Ser Ser Tyr Glu Ser Leu Ala Gly Ala Val Gly Thr Gln Tyr
1 5 10 15
<210> 34
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 34
Ala Ser Ser Leu Val Pro Asp Ala Tyr Tyr Gly Tyr Thr
1 5 10
<210> 35
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 35
Ala Ser Arg Gly Arg Arg Glu Gly Pro Thr Asp Thr Gln Tyr
1 5 10
<210> 36
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 36
Ala Ser Ser Pro Val Trp Thr Asp Gly Glu Gln Phe
1 5 10
<210> 37
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 37
Ala Ser Lys Ser Gly Thr Ser Gly Ile Pro Ser Asp Thr Gln Tyr
1 5 10 15
<210> 38
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 38
Ala Ser Ser Leu Phe Arg Thr Gly Arg Asp Ile Gln Tyr
1 5 10
<210> 39
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 39
Ala Ser Ser Glu Leu Pro Gly Gln Thr Tyr Asn Glu Gln Phe
1 5 10
<210> 40
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 40
Ala Ser Ser Phe Glu Arg Ser Gly Ser Ser Ser Tyr Glu Gln Tyr
1 5 10 15
<210> 41
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 41
Ala Ser Met Gly Ser His Tyr Gly Tyr Thr
1 5 10
<210> 42
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 42
Ala Ser Ser Met Gly Gly Val Asn Ser Ser Tyr Glu Gln Tyr
1 5 10
<210> 43
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 43
Ala Ser Glu Pro Tyr Ser Gly Gly Thr Asp Thr Gln Tyr
1 5 10
<210> 44
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 44
Ala Ser Ser Pro Gly Asp Arg Gly Ile Tyr Glu Gln Phe
1 5 10
<210> 45
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 45
Ala Ser Ser Arg Thr Gly His Lys Glu Thr Gln Tyr
1 5 10
<210> 46
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 46
Ala Ser Ser Gly Asp Arg Glu Gln Glu Thr Gln Tyr
1 5 10
<210> 47
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 47
Ala Ser Ser Thr Glu Gln Gly Pro Tyr Ser Gln Glu Thr Gln Tyr
1 5 10 15
<210> 48
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 48
Ala Ser Ser Leu Glu Ile Ser Arg Phe Gln Glu Thr Gln Tyr
1 5 10
<210> 49
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 49
Ser Ala Gly Lys Thr Arg Met Asn Thr Glu Ala Phe
1 5 10
<210> 50
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 50
Ala Ser Ser Leu Ser Leu Asp Arg Val Thr Ala Tyr Thr
1 5 10
<210> 51
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 51
Ser Ala Val Ala Gly Gln Gly Asp Tyr Gly Tyr Thr
1 5 10
<210> 52
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 52
Ser Ala Ser Gly Arg Ser Ile Leu Gly Asn Glu Gln Phe
1 5 10
<210> 53
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 53
Ala Ser Ser Leu Ser Glu Gly Ser His Tyr Gly Tyr Thr
1 5 10
<210> 54
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 54
Ala Ser Thr Leu Ala Gly Leu Ala Gly Asn Glu Gln Phe
1 5 10
<210> 55
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 55
Ala Ser Ser Ser Val Gly Ser Ser Ser Tyr Asn Ser Pro Leu His
1 5 10 15
<210> 56
<211> 17
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 56
Ala Ser Ser Phe Pro Pro Gly Leu Ala Gly Val Ser Gln Glu Thr Gln
1 5 10 15
Tyr
<210> 57
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 57
Ala Ser Ser Thr Arg Asp Phe Arg Asn Ser Pro Leu His
1 5 10
<210> 58
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 58
Ala Ser Ser Thr Glu Leu Arg Asn Glu Gln Phe
1 5 10
<210> 59
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 59
Ala Ser Ser Pro Gly Asp Ala Lys Val Asp Glu Gln Tyr
1 5 10
<210> 60
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 60
Ala Ser Thr Pro Phe Ala Gly Gly His Asn Glu Gln Phe
1 5 10
<210> 61
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 61
Ala Ser Ser Ser Thr Thr Ser Arg Gly Arg Arg Ile Tyr Glu Gln Tyr
1 5 10 15
<210> 62
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 62
Gln Gln Pro Gly Pro Arg Pro Val Gly Tyr Ala Val
1 5 10
<210> 63
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 63
Ala Ser Ser Gln Asp Asp Trp Asp Asn Ser Pro Leu His
1 5 10
<210> 64
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 64
Ala Ser Lys Gln Gly Asp Gln Phe
1 5
<210> 65
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 65
Ala Ser Ser Glu Ala Gly Ala Gly Gly Tyr Glu Gln Phe
1 5 10
<210> 66
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 66
Ser Ala Ala Gly Thr Gly Tyr Ser Glu Gln Tyr
1 5 10
<210> 67
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 67
Ala Ser Ser Val Val Ala Gly Gly Arg Gln Glu Thr Gln Tyr
1 5 10
<210> 68
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 68
Ala Ser Ser Pro Gln Gly Tyr Gly Phe Tyr Glu Gln Tyr
1 5 10
<210> 69
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 69
Ala Ser Ser Leu Leu Arg Ala Pro Thr Asp Thr Gln Tyr
1 5 10
<210> 70
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 70
Ala Ser Ser Leu Tyr Asp Arg Arg Gln Pro Gln His
1 5 10
<210> 71
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 71
Ser Ala Val Ser Asp Gly Phe Ser Tyr Glu Gln Tyr
1 5 10
<210> 72
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 72
Ala Ser Ser Pro Gly Pro Gln Pro His Tyr Glu Gln Tyr
1 5 10
<210> 73
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 73
Ala Ser Ser Ser Arg Pro Thr Gly Gly Ala Gly Ala Asn Val Leu Thr
1 5 10 15
<210> 74
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 74
Ala Ser Ser Pro Arg Arg Gln Pro Asn Met Asn Thr Gly Glu Leu Phe
1 5 10 15
<210> 75
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 75
Ser Val Tyr Arg Leu Ser Leu Asn Glu Gln Phe
1 5 10
<210> 76
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 76
Ala Ser Ser Leu Lys Val Thr Ser Asn Glu Gln Phe
1 5 10
<210> 77
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 77
Ala Ser Ser Thr Arg Leu Ala Gly Gly Ile Asp Glu Gln Phe
1 5 10
<210> 78
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 78
Ser Ala Val Thr Ser Gly Ser Pro Asn Tyr Glu Gln Tyr
1 5 10
<210> 79
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 79
Ala Ser Arg Gly Val Gln Ser Gly Tyr Glu Gln Tyr
1 5 10
<210> 80
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 80
Ala Ser Ser Ser Pro Gly Leu Thr Ser Leu Asn Thr Glu Ala Phe
1 5 10 15
<210> 81
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 81
Ala Ser Ser Leu Ala Ser Trp Met Ala Thr Asp Thr Gln Tyr
1 5 10
<210> 82
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 82
Ala Ile Ser Glu Thr Gly Gln Glu Gln His
1 5 10
<210> 83
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 83
Ala Ser Ser Leu Gly Ala Val Val Gly Thr Gln Tyr
1 5 10
<210> 84
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 84
Ala Ser Ser Pro Leu Asp Gly Gly His Leu Asp Glu Gln Tyr
1 5 10
<210> 85
<211> 8
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 85
Ala Thr Lys Gly Ser Arg Trp Tyr
1 5
<210> 86
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 86
Ala Ser Ser Phe Gly Gln Pro Gly Asn Ile Gln Tyr
1 5 10
<210> 87
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 87
Ala Ser Ser Leu Ala Gly Asp Ser Thr Pro Tyr Glu Gln Tyr
1 5 10
<210> 88
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 88
Ala Ser Ser Glu Trp Asp Arg Ile Asp Thr Gln Tyr
1 5 10
<210> 89
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 89
Ala Ser Arg Asp Gln Ala Ser Ser Gly Asn Thr Ile Tyr
1 5 10
<210> 90
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 90
Ser Ala Gly Thr Leu Ala Gly Val Asn Glu Gln Phe
1 5 10
<210> 91
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 91
Ala Ser Ser Tyr Ser Ile Thr Ser Gly Thr Ser Thr Asp Thr Gln Tyr
1 5 10 15
<210> 92
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 92
Ala Ser Ser Ser Asn Leu Ile Arg Pro Pro Tyr Glu Gln Tyr
1 5 10
<210> 93
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 93
Ala Ser Ser Ser Thr Ser Val Asp Glu Gln Tyr
1 5 10
<210> 94
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 94
Ala Val Gln Ser Tyr Ala Glu Gln Phe
1 5
<210> 95
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 95
Ala Ser Leu Ala Gly Leu Ala Gly Gly Ser Ser Tyr Asn Glu Gln Phe
1 5 10 15
<210> 96
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 96
Ala Ile Ser Glu Ser Glu Arg Leu Thr Asp Thr Gln Tyr
1 5 10
<210> 97
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 97
Ala Ser Thr Pro Glu Ala Thr Ser Val Glu Gln Tyr
1 5 10
<210> 98
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 98
Ser Val Glu Asp Arg Tyr Gly Gly Glu Leu Phe
1 5 10
<210> 99
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 99
Ala Ser Ser Glu Leu Phe Pro Ser Gln Thr Gly Thr Pro Leu His
1 5 10 15
<210> 100
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 100
Ala Ser Thr Lys Thr Gly Gly Leu Gly Ser Tyr Asn Glu Gln Phe
1 5 10 15
Claims (7)
1.一种宫颈癌的外周血TCR标志物,其特征在于,所述标志物包括序列为SEQ ID NO.1~100所示的蛋白中的至少一种。
2.根据权利要求1所述的宫颈癌的外周血TCR标志物,其特征在于,所述标志物的蛋白序列为SEQ ID NO.1~100所示的序列经取代、缺失和/或替换一个或多个碱基后,能表达相同功能的蛋白。
3.权利要求1所述的标志物在制备治疗宫颈癌的制剂中的应用。
4.根据权利要求3所述的应用,其特征在于,所述制剂包括含有该标志物的T细胞受体,或能表达产生该标志物的T细胞受体的质粒、病毒载体或核酸片段。
5.一种用于宫颈癌检测的试剂盒,其特征在于,包括能与权利要求1所述标志物发生特异性结合的抗体。
6.一种制剂,其特征在于,包括能与权利要求1所述标志物发生特异性结合的抗体。
7.一种检测宫颈癌的蛋白质芯片,其特征在于,所述蛋白质芯片包括基片和点样在基片上特异性抗体,所述特异性抗体为能与权利要求1所述标志物发生特异性结合的抗体。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010665303.0A CN111650373A (zh) | 2020-07-11 | 2020-07-11 | 一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 |
PCT/CN2021/101678 WO2022012283A1 (zh) | 2020-07-11 | 2021-06-23 | 一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010665303.0A CN111650373A (zh) | 2020-07-11 | 2020-07-11 | 一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111650373A true CN111650373A (zh) | 2020-09-11 |
Family
ID=72347686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010665303.0A Pending CN111650373A (zh) | 2020-07-11 | 2020-07-11 | 一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111650373A (zh) |
WO (1) | WO2022012283A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113109564A (zh) * | 2021-03-15 | 2021-07-13 | 成都益安博生物技术有限公司 | 一种急性髓细胞性白血病的外周血tcr标志物及其检测试剂盒和应用 |
CN113567682A (zh) * | 2021-07-23 | 2021-10-29 | 成都益安博生物技术有限公司 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
WO2022012283A1 (zh) * | 2020-07-11 | 2022-01-20 | 成都益安博生物技术有限公司 | 一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 |
WO2022194039A1 (zh) * | 2021-03-15 | 2022-09-22 | 成都益安博生物技术有限公司 | 一种急性b淋巴细胞白血病的外周血tcr标志物及其检测试剂盒和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005008248A2 (en) * | 2003-07-18 | 2005-01-27 | Georgetown University | Diagnosis and treatment of cervical cancer |
WO2016015059A1 (en) * | 2014-07-25 | 2016-01-28 | OncoGenesis Inc. | Systems and methods for early detection of cervical cancer by multiplex protein biomarkers |
CN109932510B (zh) * | 2017-12-18 | 2022-07-12 | 天津云检医学检验所有限公司 | 一种宫颈癌生物标志物及其检测试剂盒 |
CN110331201B (zh) * | 2019-07-26 | 2022-04-08 | 泗水县人民医院 | 宫颈鳞癌相关生物标志物及其应用 |
CN111650373A (zh) * | 2020-07-11 | 2020-09-11 | 成都益安博生物技术有限公司 | 一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 |
-
2020
- 2020-07-11 CN CN202010665303.0A patent/CN111650373A/zh active Pending
-
2021
- 2021-06-23 WO PCT/CN2021/101678 patent/WO2022012283A1/zh active Application Filing
Non-Patent Citations (5)
Title |
---|
中国科协学会学术部: "《网络药理学-中药现代化的新思路与新方法》", 30 November 2014, 中国科学技术出版社, pages: 12 - 14 * |
王继贤 等: "《临床生化检验(第二版)》", 31 July 1996, 湖南科学技术出版社, pages: 260 - 261 * |
程书钧: "《癌前病变和癌前癌症》", 31 January 2017, 河南科学技术出版社, pages: 39 - 40 * |
胡智祥: "《医院临床检验技术操作规范与实(化)验室管理全书》", 31 August 2004, 银声音像出版社, pages: 110 - 113 * |
董吁钢 等: "《心血管疾病预防与康复》", 28 February 2013, 中山大学出版社, pages: 25 - 26 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022012283A1 (zh) * | 2020-07-11 | 2022-01-20 | 成都益安博生物技术有限公司 | 一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 |
CN113109564A (zh) * | 2021-03-15 | 2021-07-13 | 成都益安博生物技术有限公司 | 一种急性髓细胞性白血病的外周血tcr标志物及其检测试剂盒和应用 |
WO2022194039A1 (zh) * | 2021-03-15 | 2022-09-22 | 成都益安博生物技术有限公司 | 一种急性b淋巴细胞白血病的外周血tcr标志物及其检测试剂盒和应用 |
CN113567682A (zh) * | 2021-07-23 | 2021-10-29 | 成都益安博生物技术有限公司 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
WO2023000688A1 (zh) * | 2021-07-23 | 2023-01-26 | 成都益安博生物技术有限公司 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2022012283A1 (zh) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111650373A (zh) | 一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022012284A1 (zh) | 一种黑色素瘤的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022012289A1 (zh) | 一种卵巢癌的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022012280A1 (zh) | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022012291A1 (zh) | 一种乳腺癌的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022012293A1 (zh) | 一种子宫内膜癌的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022012279A1 (zh) | 一种大肠癌的外周血tcr标志物序列及其检测试剂盒和应用 | |
WO2022012292A1 (zh) | 一种胰腺癌的外周血tcr标志物及其检测试剂盒和应用 | |
CN104004840B (zh) | 用于早期筛查与诊断前列腺癌的试剂盒 | |
WO2022012290A1 (zh) | 一种前列腺癌的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022194033A1 (zh) | 一种弥漫大b细胞淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 | |
WO2022194036A1 (zh) | 一种经典霍奇金淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 | |
Lakshmi et al. | Study and analysis of two hundred cervical PAP smears in our hospital | |
CN112321700A (zh) | 一种新型冠状病毒感染的外周血tcr标志物及其检测试剂盒和应用 | |
Joshi et al. | PAP smear and HPV co-testing-need of the hour | |
CN103243113A (zh) | Dna分子、扩增该dna分子的引物组、包含该引物组的试剂盒及其使用方法 | |
Butorac et al. | Prediction of cervical epithelial lesions level in patients with positive cytologic findings using colposcopic classification Rio De Janeiro 2011 | |
Jadav et al. | A study of cervical pap smear in tertiary care hospital of Ahmedabad, Gujarat, India | |
Begum et al. | Correlation of Pap Smear and Colposcopy in Relation to Histopathological Findings in Detection of Preinvasive Lesion of Cervix in Bangabandhu Sheikh Mujib Medical University Hospital Dhaka Bangladesh | |
Ahuja et al. | PREDICTION OF HIGH GRADE CIN LESIONS USING COLPOSCOPIC SWEDE SCORE | |
CN118330217A (zh) | 外周血免疫细胞在宫颈病变诊断中的标志物及用途 | |
CN117904296A (zh) | 基于外周血免疫细胞的hpv16/18相关cin2/3和子宫颈癌的诊断标志物、筛选方法及用途 | |
Alan et al. | Importance of atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion (ASC-H) | |
Frost | Cytobrush in evaluation of cervical dysplasia: is cervical curettage necessary? | |
Kramer et al. | “Anaplasia Clinic”. Aid in the diagnosis and treatment of pre‐invasive cervical lesions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |